GW Pharmaceuticals

(NASDAQ: GWPH)
Healthcare  |  Drug Manufacturers—General
91.72 5.14 5.94%
Stock Price | April 7, 2020, 4 p.m.
14 Followers
Bid: 91.0
Ask: 94.0
Prev. Close: 86.58
52 Week Low: 67.98
52 Week High: 196.0
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

GW Pharmaceuticals PLC is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The company's lead product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol used for the treatment of a number of rare childhood-onset epilepsy disorders. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. Geographically its presence can be seen across the region of UK, Europe, US, Canada, and others.

Read more Read less

Recently Viewed Tickers

Premium Cannabis Stocks Review - Pre-Market Edition 04/08/20

2 Comments
an hour ago

Premium Cannabis Stocks Review - AM Edition 04/07/20

2 Comments
8 hours ago

Premium Cannabis Stocks Review - Weekend Edition 04/06/20

4 Comments
3 days ago

Premium Cannabis Sub-Sector Review - 04/03/20

3 days ago

Premium Weekly Review 04/03/20

4 days ago

Premium Mid-Week Chat 04/01/20

1 Comments
5 days ago

Premium Cannabis Stocks Review - AM Edition 04/01/20

7 Comments
6 days ago

Premium Cannabis Stocks Review - AM Edition 03/31/20

15 Comments
1 week ago

Premium How COVID-19 Will Impact the American Cannabis Industry

2 Comments
1 week ago

Premium Changes to the Global Cannabis Stock Index for April 2020

3 Comments
1 week ago